SUNNYVALE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Prodeon Medical, Inc., a medical device company developing a minimally invasive treatment for lower urinary tract symptoms (LUTS) attributed to ...
The MarketWatch News Department was not involved in the creation of this content. SUNNYVALE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Prodeon Medical, a privately held medical device company focused ...
The Expander-2 trial randomly assigned men with BPH symptoms at 23 sites in the US and Canada to receive a temporary nitinol urethral implant, Urocross Expander, or a sham procedure.
SAN JOSE, Calif., April 28, 2026 (GLOBE NEWSWIRE)-- Prodeon Medical, a medical device company developing minimally invasive treatments for benign prostatic hyperplasia (BPH), today announces that ...
(MENAFN- GlobeNewsWire - Nasdaq) Company's prospective, multi-center 240-patient, pivotal randomized controlled trial (RCT) earns AUA“Practice-changing, Paradigm-shifting Clinical Trials in Urology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results